Hims & Hers Health (NYSE:HIMS – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations for Hims & Hers Health and MDxHealth, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hims & Hers Health | 3 | 7 | 2 | 0 | 1.92 |
| MDxHealth | 0 | 0 | 3 | 0 | 3.00 |
Hims & Hers Health currently has a consensus price target of $39.8333, suggesting a potential downside of 13.57%. MDxHealth has a consensus price target of $7.00, suggesting a potential upside of 145.61%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Hims & Hers Health.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hims & Hers Health | $1.48 billion | 6.99 | $126.04 million | $0.80 | 57.61 |
| MDxHealth | $90.05 million | 1.50 | -$38.07 million | ($0.88) | -3.24 |
Hims & Hers Health has higher revenue and earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Hims & Hers Health and MDxHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hims & Hers Health | 9.63% | 26.26% | 13.06% |
| MDxHealth | -34.98% | -274.67% | -21.21% |
Risk & Volatility
Hims & Hers Health has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
Insider and Institutional Ownership
63.5% of Hims & Hers Health shares are owned by institutional investors. 13.7% of Hims & Hers Health shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Hims & Hers Health beats MDxHealth on 11 of the 14 factors compared between the two stocks.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
